Greenwich LifeSciences, Inc.
GLSI
$22.23
$0.582.68%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -10.70% | -5.24% | 65.77% | 61.67% | 48.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.51% | 7.35% | 92.30% | 82.71% | 85.67% |
| Operating Income | -22.51% | -7.35% | -92.30% | -82.71% | -85.67% |
| Income Before Tax | -23.02% | -8.21% | -96.16% | -86.96% | -91.40% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.02% | -8.21% | -96.16% | -86.96% | -91.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.02% | -8.21% | -96.16% | -86.96% | -91.40% |
| EBIT | -22.51% | -7.35% | -92.30% | -82.71% | -85.67% |
| EBITDA | -22.53% | -7.37% | -92.34% | -82.74% | -85.70% |
| EPS Basic | -15.80% | -3.69% | -90.94% | -82.25% | -87.57% |
| Normalized Basic EPS | -15.82% | -3.69% | -90.98% | -82.31% | -87.58% |
| EPS Diluted | -15.80% | -3.69% | -90.94% | -82.25% | -87.57% |
| Normalized Diluted EPS | -15.82% | -3.69% | -90.98% | -82.31% | -87.58% |
| Average Basic Shares Outstanding | 6.03% | 3.99% | 3.04% | 2.66% | 1.88% |
| Average Diluted Shares Outstanding | 6.03% | 3.99% | 3.04% | 2.66% | 1.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |